Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
- PMID: 23479136
- DOI: 10.1007/s00280-013-2129-6
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
Abstract
Purpose: To evaluate first-generation rapamycin analogs (everolimus, temsirolimus, and rapamycin) and second-generation drugs inhibiting mTOR kinase (AZD-8055), PI3K (BKM-120) or both (BEZ-235 and GDC-0980) in hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) cells characterized for acquired resistance to sorafenib or sunitinib.
Methods: Anti-proliferative (MTT assay) and cell signaling (Western blot) effects of rapamycin analogs (1-20 μM) and second-generation drugs (0.03-20.0 μM) were assessed in human HCC SK-HEP1, RCC 786-0, and sorafenib- (SK-Sora) or sunitinib-resistant (786-Suni) cells.
Results: In SK-HEP1 cells displaying high PTEN and Bcl2 expression, rapamycin analogs had poor anti-proliferative effects. However, SK-Sora cells were more sensitive to rapamycin analogs (≥1 μM) than SK-HEP1 cells. In 786-0 cells, lacking PTEN and Bcl2 expression, ≥1 μM rapamycin analogs blocked mTORC1 signaling, transiently activated Akt, and inhibited cell proliferation. Protracted sunitinib exposure in 786-Suni cells yielded an increase in p27 expression and a decreased sensitivity to rapamycin analogs, although mTORC1 function could be inhibited with rapamycin analogs. Second-generation drugs induced more potent growth inhibition than rapamycin analogs at concentrations >0.03 μM in parental cells, SK-Sora, and 786-Suni cells. Growth inhibitory concentrations of these new drugs also blocked mTORC1 downstream targets.
Conclusions: Rapamycin analogs inhibited mTORC1 downstream targets and yielded anti-proliferative effects in HCC and RCC cells. Second-generation drugs also appeared to be potent inhibitors of mTORC1 signaling; however, they appeared to be far more potent in inhibiting cellular proliferation in parental HCC and RCC cells and in cells developing resistance to sorafenib or sunitinib.
Similar articles
-
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.J Cell Mol Med. 2015 Feb;19(2):430-41. doi: 10.1111/jcmm.12471. Epub 2014 Dec 2. J Cell Mol Med. 2015. PMID: 25444514 Free PMC article.
-
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.J Surg Res. 2012 Aug;176(2):542-8. doi: 10.1016/j.jss.2011.10.045. Epub 2011 Nov 21. J Surg Res. 2012. PMID: 22261591
-
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.J BUON. 2007 Sep;12 Suppl 1:S151-62. J BUON. 2007. PMID: 17935273 Review.
-
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.Mol Cancer Ther. 2016 Nov;15(11):2553-2562. doi: 10.1158/1535-7163.MCT-15-0976. Epub 2016 Aug 5. Mol Cancer Ther. 2016. PMID: 27496136 Free PMC article.
-
Current development of the second generation of mTOR inhibitors as anticancer agents.Chin J Cancer. 2012 Jan;31(1):8-18. doi: 10.5732/cjc.011.10281. Epub 2011 Nov 4. Chin J Cancer. 2012. PMID: 22059905 Free PMC article. Review.
Cited by
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992. Sci Rep. 2016. PMID: 27623107 Free PMC article.
-
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.J Cell Mol Med. 2015 Feb;19(2):430-41. doi: 10.1111/jcmm.12471. Epub 2014 Dec 2. J Cell Mol Med. 2015. PMID: 25444514 Free PMC article.
-
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Oncotarget. 2015 Oct 6;6(30):28867-81. doi: 10.18632/oncotarget.4814. Oncotarget. 2015. PMID: 26311740 Free PMC article.
-
mTOR Inhibitors at a Glance.Mol Cell Pharmacol. 2015;7(2):15-20. Mol Cell Pharmacol. 2015. PMID: 27134695 Free PMC article.
-
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.Cancer. 2016 Aug 1;122(15):2389-98. doi: 10.1002/cncr.30056. Epub 2016 May 19. Cancer. 2016. PMID: 27198170 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous